Skip to main content

Table 7 MTX efficacy in relation to prior disease duration, dose and route of administration

From: Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

Publication No of patients Prior disease duration MTX dose (route) ACRpedi70 (%)/CID (%)
Treatment duration (months)
   6 12
Ruperto 2004 [33] 595 2.7 yrs (mean) 10 ± 2.3 mg/m2 (78 % p.o.) 38/12b  
40   14.5 ± 1.3 mg/m2 (s.c., i.m.)a   45/12.5b
40   28.5 ± 2.5 mg/m2 (s.c., i.m.)a   47.5/10b
Bartoli 2007 [61] 125 1.45 yrs (med) 10 mg/m2 (NA) 26.4/NA  
Tynjala 2011 [62]c 20 1.5 mo (mean) 15–30 mg/m2 (p.o.,s.c.)   60/25
Klein 2012 [50] 259 1.1 yrs (med) 0,4 mg/kg (p.o.) 51/NA 66/NA
152 0.8 yrs (med) 0.42 mg/kg (s.c.) 53/NA  
Bulatovič 2012 [13] 104 ≥1 yrs 9.8 mg/m2 (NA) 38.5/NA 50/NA
Wallace 2012 [43] 43 5.2 mo (mean) 0.5 mg/kg (s.c.) NA/23.3 NA/16.3
Moncrieffe2013 [51] 87 1.3 yrs (med) 10–15 mg/m2 (70 % p.o.) 56.3/NA  
Pastore 2015 [53] 69 1.0 yrs (med) 15 mg/m2 (62 % p.o.) 52.2/NA  
Fraňova 2016 55 3.5 mo (med) 14.2 mg/m2 (18 % p.o.) 50.9/30.9 70.9/56.4
  1. MTX, Methotrexate
  2. CID, Clinical Inactive Disease [40]
  3. NA, Not available
  4. aPatients were non-responders to the dose of 10 ± 2.3 mg/m2 after the first 6 months
  5. bCriteria for inactive disease: Absence of active arthritis and ESR < 20 mm/h
  6. cDose 15 mg/m2 orally, non-responders at 3 months switched to 30 mg/m2 s.c